

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

I, ADRIAN PAUL BROWN, M.A., M.C.I.L., M.I.T.I., declare

1. That I am a citizen of the United Kingdom of Great Britain and Northern Ireland, residing at 5 Gilbert Road, London, SE11 4NZ.
2. That I am well acquainted with the French and English languages.
3. That the attached is a true translation into the English language of the certified copy of European Patent Application No. 03292864.0 filed on 19<sup>th</sup> November 2003.
4. That all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardise the validity of the patent application in the United States of America or any patent issuing thereon.

DECLARED THIS 20<sup>th</sup> DAY OF MARCH 2006



A P BROWN



---

**European  
Patent Office**

## **Certificate**

The attached documents  
are exact copies of the  
European patent application  
described on the following  
page, as originally filed.

---

**Patent application No.**

03292864.0

For the President of the  
European Patent Office

[signature]

**R C van Dijk**



European  
Patent Office

Application no.: 03292864.0

Date of filing: 19.11.03

Applicant(s):

LES LABORATOIRES SERVIER  
12, place de la Défense  
92415 Courbevoie Cédex  
FRANCE

Title of the invention:  
(If no title is shown please refer to the description.)

New process for the synthesis of perindopril and pharmaceutically acceptable salts thereof

Priority(ies) claimed  
State/Date/File no.:

International Patent classification:

C07D209/00

Contracting states designated at date of filing:


AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL  
PT RO SE SI SK TR LI

**NEW PROCESS FOR THE SYNTHESIS OF PERINDOPRIL  
AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF**

**LES LABORATOIRES SERVIER  
12, PLACE DE LA DEFENSE  
F-92415 COURBEVOIE CEDEX**

**INVENTORS :      Thierry DUBUFFET  
                         Pascal LANGLOIS**

The present invention relates to a process for the synthesis of perindopril of formula (I) :



and pharmaceutically acceptable salts thereof.

Perindopril and its pharmaceutically acceptable salts, and more especially its tert-butylamine salt, have valuable pharmacological properties.

Their principal property is that of inhibiting angiotensin I converting enzyme (or kininase II), which allows, on the one hand, prevention of the conversion of the decapeptide angiotensin I to the octapeptide angiotensin II (a vasoconstrictor) and, on the other hand, prevention of the degradation of bradykinin (a vasodilator) to an inactive peptide.

Those two actions contribute to the beneficial effects of perindopril in cardiovascular diseases, more especially in arterial hypertension and heart failure.

Perindopril, its preparation and its use in therapeutics have been described in European patent specification EP 0 049 658.


In view of the pharmaceutical value of this compound, it has been important to be able to obtain it by an effective synthesis process, readily transposable to an industrial scale, that leads to perindopril in a good yield and with excellent purity starting from reasonably priced starting materials.

Patent specification EP 0 308 341 describes the industrial synthesis of perindopril by the coupling of (2S,3aS,7aS)-octahydroindole-2-carboxylic acid benzyl ester with N-[(S)-1-

carboxybutyl]-(*S*)-alanine ethyl ester, followed by deprotection of the carboxylic group of the heterocycle by catalytic hydrogenation.


The Applicant has now developed a new process for the synthesis of perindopril that uses readily obtainable starting materials.

- 5 More specifically, the present invention relates to a process for the synthesis of perindopril and pharmaceutically acceptable salts thereof, which process is characterised in that the compound of formula (II), of configuration (*S*) :



wherein R represents a hydrogen atom or a protecting group for the acid function,


- 10 is reacted with a compound of formula (III), of configuration (*R*) :



wherein G represents a chlorine or bromine atom or a hydroxy, *p*-toluenesulphonyloxy, methanesulphonyloxy or trifluoromethanesulphonyloxy group,


in the presence of a base

- 15 to yield the compound of formula (IV) :



wherein R and G are as defined hereinbefore,


which is subjected to an intramolecular coupling reaction to yield the compound of formula (V) :




5

wherein R and G are as defined hereinbefore,

which is reacted with the compound of formula (VI) :



to yield the compound of formula (VII) :



10

wherein R is as defined hereinbefore,

which is subjected to a catalytic hydrogenation reaction to yield, after deprotection where appropriate, the compound of formula (I).

Among the protecting groups for the acid function there may be mentioned, without implying any limitation, the groups benzyl and linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkyl.

15

Among the bases that can be used for the reaction between the compounds of formula (II) and (III) there may be mentioned, without implying any limitation, organic amines, such as triethylamine, pyridine or diisopropylethylamine, and mineral bases, such as NaOH, KOH, Na<sub>2</sub>CO<sub>3</sub>, K<sub>2</sub>CO<sub>3</sub>, NaHCO<sub>3</sub> or KHCO<sub>3</sub>.

- 5 The intramolecular coupling reaction is preferably carried out either in the presence of a base and a catalyst based on palladium or using sodium hydride and copper(I) iodide or copper(I) bromide.

The catalysts based on palladium which are preferably used in the coupling reaction are catalysts based on palladium and on an arylphosphine or bisphosphine.

- 10 Among those catalysts there may be mentioned, without implying any limitation, Pd(0)/PPh<sub>3</sub>, Pd(0)/P(*o*-tolyl)<sub>3</sub>, Pd(0)/P(1-naphthyl)<sub>3</sub>, Pd(0)/P(*o*-methoxyphenyl)<sub>3</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>/PPh<sub>3</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>/P(*o*-tolyl)<sub>3</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>/P(1-naphthyl)<sub>3</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>/P(*o*-methoxyphenyl)<sub>3</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>/P(2-furyl)<sub>3</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>/dppp, Pd<sub>2</sub>(dba)<sub>3</sub>/(±)-BINAP and (DPPF)PdCl<sub>2</sub>.CH<sub>2</sub>Cl<sub>2</sub>/DPPF,

- 15 BINAP being understood to be 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl,  
dba being understood to be dibenzylideneacetone,  
DPPF being understood to be 1,1'-bis(diphenylphosphino)ferrocene  
and dppp being understood to be 1,3-bis(diphenylphosphino)propane.

- 20 Among the bases that can be used for the coupling reaction in the presence of a catalyst based on palladium there may be mentioned, without implying any limitation, Cs<sub>2</sub>CO<sub>3</sub>, NaOtBu, Na<sub>2</sub>CO<sub>3</sub>, NaOAc and KOAc.

- When G represents a chlorine or bromine atom or a *p*-toluenesulphonyloxy, methanesulphonyloxy or trifluoromethanesulphonyloxy group, the reaction between the compounds of formulae (V) and (VI) is preferably carried out in the presence of a base,  
25 preferably an organic amine, such as triethylamine, pyridine or diisopropylethylamine, or a mineral base, such as Na<sub>2</sub>CO<sub>3</sub>, K<sub>2</sub>CO<sub>3</sub>, NaHCO<sub>3</sub> or KHCO<sub>3</sub>.



When G represents a hydroxy group, the reaction between the compounds of formulae (V) and (VI) is preferably carried out in the presence of an activation reagent, such as N-methyl-N-phenyl-aminotriphenylphosphonium iodide, or, when R is other than a hydrogen atom, by a Mitsunobu reaction.

- 5 The compounds of formula (IV) are new products which are useful as synthesis intermediates in the chemical or pharmaceutical industry, especially in the synthesis of perindopril, and as such form an integral part of the present invention.

The compounds of formula (II) can be prepared according to the procedure described in the publication *J. Am. Chem. Soc.* **1994**, *116*, 10847-10848.

10 **EXAMPLE 1:** (2S, 3aS, 7aS)-1-{(2S)-2-[(1S)-1-(Ethoxycarbonyl)-butylamino]-propionyl}-octahydro-1*H*-indole-2-carboxylic acid tert-butylamine salt

15 *Step A:* Benzyl (2S)-3-(2-bromophenyl)-2-{[(2R)-2-bromopropanoyl]amino}-propanoate

- Introduce 25.7 g of benzyl (S)-2-bromophenylalaninate and 150 ml of dichloromethane into a reactor, then bring the temperature of the reaction mixture to 0°C and add 20 ml of diisopropylethylamine followed by 13.2 g of (2R)-2-bromopropionyl chloride.
- 20 Subsequently, bring the mixture to ambient temperature. After stirring for 1 hour at that temperature, wash the mixture with water and then with dilute acetic acid solution, and evaporate off the solvents to yield the title compound.

*Step B:* Benzyl (2S)-1-[(2R)-2-bromopropanoyl]-2-indolinecarboxylate

- Introduce 15.5 g of the compound obtained in the Step above, dissolved in toluene, 1.57 g of Pd<sub>2</sub>(dba)<sub>3</sub>, 1.83 g of P(o-tolyl)<sub>3</sub> and 21.5 g of Cs<sub>2</sub>CO<sub>3</sub> into a reactor. Then bring the
- 25 reaction mixture to 100°C. After stirring for 15 hours at that temperature, the mixture is

brought back to ambient temperature and purified by chromatography over silica to yield the title compound.

*Step C : Benzyl (2S)-1-((2S)-2-[(1S)-1-(ethoxycarbonyl)butyl]amino)-propanoyl)-2-indolinecarboxylate*

- 5 Introduce 12.3 g of ethyl (2S)-2-aminopentanoate, 16 ml of triethylamine and 16 ml of acetonitrile into a reactor; then bring the mixture to 60°C, slowly add a solution of 19.4 g of the compound obtained in the Step above, dissolved in dichloromethane, and reflux for 4 hours. After returning to ambient temperature, wash the mixture with water and with dilute acetic acid solution; then evaporate off the solvents to yield the title compound.

10 *Step D : (2S, 3aS, 7aS)-1-((2S)-2-[(1S)-1-(Ethoxycarbonyl)-butylamino]-propionyl)-octahydro-1H-indole-2-carboxylic acid*

Introduce 20 g of the compound obtained in the Step above, dissolved in acetic acid, and then 0.5 g of 10 % Pd/C into a hydrogenator. Hydrogenate under a pressure of 0.5 bar between 15 and 30°C, until the theoretical amount of hydrogen has been absorbed.

- 15 Remove the catalyst by filtration and then cool to between 0 and 5°C and collect the resulting solid by filtration. Wash the cake and dry it to constant weight to yield the title compound with an enantiomeric purity of 99 %.

*Step E : (2S, 3aS, 7aS)-1-((2S)-2-[(1S)-1-(Ethoxycarbonyl)-butylamino]-propionyl)-octahydro-1H-indole-2-carboxylic acid tert-butylamine salt*

- 20 The precipitate obtained in the Step above (20 g) is dissolved in 280 ml of ethyl acetate, and then 4 g of tert-butylamine and 40 ml of ethyl acetate are added.  
The resulting suspension is then refluxed until dissolution is complete; then the resulting solution is filtered whilst hot and cooled to a temperature of 15-20°C, with stirring.  
The precipitate obtained is then filtered off, made into a paste again using ethyl acetate,  
25 dried and then ground to yield the expected product in a yield of 95 %.

**EXAMPLE 2 :**      **(2S, 3aS, 7aS)-1-((2S)-2-((1S)-1-(Ethoxycarbonyl)-butylamino)-propionyl)-octahydro-1H-indole-2-carboxylic acid tert-butylamine salt**

Step A :      *(2S)-3-(2-Bromophenyl)-2-([(2R)-2-bromopropanoyl]amino)-propanoic acid*

Introduce 28.8 g of (S)-2-bromophenylalanine, 7.5 ml of water and 15 ml of toluene into a reactor; then bring the mixture to between 0 and 5°C and add 25 ml of 5M sodium hydroxide solution and then a solution of 20.2 g of (2R)-2-bromopropanoyl chloride in toluene, whilst keeping the temperature below 10°C and maintaining the pH of the mixture at 10 by adding 5M sodium hydroxide solution. After stirring for a further 1 hour at 10°C, add concentrated hydrochloric acid to bring the pH of the mixture to 6.

Separate off the toluene phase and then add concentrated hydrochloric acid to the aqueous phase to bring the pH to 2.

The precipitate formed is then filtered off and dried to yield the title compound.

Step B :      *Identical to Step B of Example 1.*

Step C :      *(2S)-1-((2S)-2-([(1S)-1-(Ethoxycarbonyl)-butyl]-amino)-propanoyl)-2-indolinecarboxylic acid*

Introduce 10.5 g of ethyl (2S)-2-aminopentanoate, 13.5 ml of triethylamine and 13.5 ml of acetonitrile into a reactor; then bring the mixture to 60°C and slowly add a solution of 19.3 g of the compound obtained in the Step above in 130 ml of dichloromethane, and then reflux for 4 hours. After returning to ambient temperature, wash the mixture with water and with dilute acetic acid solution; then evaporate off the solvents to yield the title compound.

Steps D and E : *Identical to Steps D and E of Example 1.*

**EXAMPLE 3 : (2S, 3aS, 7aS)-1-((2S)-2-((1S)-1-(Ethoxycarbonyl)-butylamino)-propionyl)-octahydro-1H-indole-2-carboxylic acid tert-butylamine salt**

Step A :      *Benzyl (2S)-3-(2-bromophenyl)-2-([(2R)-2-(p-toluenesulphonyloxy)-propanoyl]-amino)-propanoate*


5

Introduce 25.7 g of benzyl (R)-2-bromophenylalaninate and 150 ml of dichloromethane into a reactor; then bring the temperature of the reaction mixture to 0°C and add 20 ml of diisopropylethylamine and then 20.2 g of (1R)-2-chloro-1-methyl-2-oxoethyl-p-toluenesulphonate chloride. Then bring the mixture to ambient temperature. After stirring  
10 for 1 hour at that temperature, wash the mixture with water. The solvents are then evaporated off to yield the title compound.

Steps B to E : *Identical to Steps B to E of Example 1.*


**CLAIMS**

1. Process for the synthesis of the compounds of formula (I) :




and pharmaceutically acceptable salts thereof,

5 characterised in that the compound of formula (II), of configuration (S) :



wherein R represents a hydrogen atom or a protecting group for the acid function,


is reacted with a compound of formula (III), of configuration (R) :



10 wherein G represents a chlorine or bromine atom or a hydroxy, p-toluenesulphonyloxy, methanesulphonyloxy or trifluoromethanesulphonyloxy group,


in the presence of a base

to yield the compound of formula (IV) :




wherein R and G are as defined hereinbefore,

which is subjected to an intramolecular coupling reaction to yield the compound of formula (V) :




wherein R and G are as defined hereinbefore,

which is reacted with the compound of formula (VI) :



to yield the compound of formula (VII) :



wherein R is as defined hereinbefore,

which is subjected to a catalytic hydrogenation reaction to yield, after deprotection where appropriate, the compound of formula (I).


2. Synthesis process according to claim 1, characterised in that R represents a benzyl or linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkyl group.
- 5 3. Synthesis process according to claim 1, characterised in that the intramolecular coupling reaction is carried out either in the presence of a base and a catalyst based on palladium or using sodium hydride and copper(I) iodide or copper(I) bromide.
4. Synthesis process according to claim 3, characterised in that the intramolecular coupling reaction is carried out in the presence of a base and a catalyst based on  
10 palladium and on an arylphosphine or bisphosphine.
5. Synthesis process according to claim 4, characterised in that the base used for the intramolecular coupling reaction is selected from Cs<sub>2</sub>CO<sub>3</sub>, NaOtBu, Na<sub>2</sub>CO<sub>3</sub>, NaOAc and KOAc.
6. Synthesis process according to claim 4 or 5, characterised in that the catalyst based on  
15 palladium and on an arylphosphine or bisphosphine is selected from Pd(0)/PPh<sub>3</sub>, Pd(0)/P(*o*-tolyl)<sub>3</sub>, Pd(0)/P(1-naphthyl)<sub>3</sub>, Pd(0)/P(*o*-methoxyphenyl)<sub>3</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>/PPh<sub>3</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>/P(*o*-tolyl)<sub>3</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>/P(1-naphthyl)<sub>3</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>/P(*o*-methoxyphenyl)<sub>3</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>/P(2-furyl)<sub>3</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>/dppp, Pd<sub>2</sub>(dba)<sub>3</sub>/(±)-BINAP and (DPPF)PdCl<sub>2</sub>.CH<sub>2</sub>Cl<sub>2</sub>/DPPF,  
20 BINAP being understood to be 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, dba being understood to be dibenzylideneacetone, DPPF being understood to be 1,1'-bis(diphenylphosphino)ferrocene and dppp being understood to be 1,3-bis(diphenylphosphino)propane.
7. Synthesis process according to claim 1, characterised in that G represents a chlorine or  
25 bromine atom or a *p*-toluenesulphonyloxy, methanesulphonyloxy or trifluoromethanesulphonyloxy group.

8. Synthesis process according to claim 7, characterised in that the reaction between the compounds of formulae (V) and (VI) is carried out in the presence of an organic amine selected from triethylamine, pyridine and diisopropylethylamine or a mineral base selected from  $\text{Na}_2\text{CO}_3$ ,  $\text{K}_2\text{CO}_3$ ,  $\text{NaHCO}_3$  and  $\text{KHCO}_3$ .

5 9. Synthesis process according to claim 1, characterised in that G represents a hydroxy group.

10 10. Synthesis process according to claim 9, characterised in that the reaction between the compounds of formulae (V) and (VI) is carried out in the presence of N-methyl-N-phenyl-aminotriphenylphosphonium iodide or, when R is other than a hydrogen atom, by a Mitsunobu reaction.

11. Compound of formula (IV) :



wherein R and G are as defined in claim 1.


15 12. Process according to any one of claims 1 to 10 for the synthesis of perindopril in the form of its tert-butylamine salt.



**ABSTRACT**

**NEW PROCESS FOR THE SYNTHESIS OF PERINDOPRIL  
AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF**

Process for the synthesis of perindopril of formula (I) :



5

and pharmaceutically acceptable salts thereof.